Dimerization of FGFR1 point mutants with enhanced kinase activity Authored: Rothfels, K, 2012-02-09 Edited: Rothfels, K, 2012-05-16 Large scale genomic characterization of glioblastoma tumors has identified three point mutants in the kinase domain of FGFR1: N546K, R576W and K656E (Rand, 2005, TCGA, 2008), representing the first kinase domain point mutants identified in this gene in any cancer. These mutants are believed or have been shown to have enhanced kinase activity and to be able to function in a ligand-independent manner (Petiot, 2002; Lew, 2009; Raffioni, 1998, Rand, 2005; Hart, 2000) Pubmed10918587 Pubmed12112473 Pubmed16186508 Pubmed18772890 Pubmed19224897 Pubmed9857065 Reactome Database ID Release 432023456 Reactome, http://www.reactome.org ReactomeREACT_120981 Reviewed: Ezzat, S, 2012-05-15 has a Stoichiometric coefficient of 2 FGFR1 mutant dimers with enhanced kinase activity FGFR1 mutants with enhanced kinase activity